Return to Latest Press Releases

 

Akrimax Pharmaceuticals Announces the 2015 IBSA Foundation Fellowship Program

Dedicated investigators are given the opportunity to receive research grants

Cranford, NJ (July, 2015) – Akrimax Pharmaceuticals and Institut Biochimique (IBSA) announce the availability of the 2015 IBSA Foundation Fellowship Program. The program will grant fellowships worth ϵ24,000 ($26,800) to five young medical researchers (under 35 years old) for research conducted in the areas of dermatology, endocrinology, fertility/infertility, orthopedics/rheumatology and pain medicine. The grant will cover research conducted over a twelve month period. Details about the program and an application can be obtained thru the IBSA Foundation at www.ibsafoundation.org.

Since 2013, The IBSA Foundation has annually provided funding for young investigators to continue their post-doctoral medical research. Keith Rotenberg, Corporate Vice President and Chief Scientific Officer of Akrimax: “We’re delighted to work with IBSA to further the careers of young medical researchers. We see this innovative program as an investment in the future. These are the scientists who will discover tomorrow’s medical breakthroughs”.

The deadline for submitting proposals is no later than December 31, 2015. An international scientific board will evaluate submitted proposals and make will make recommendations that the IBSA Foundation Direction will consider when making its final decisions as to which individuals will be awarded fellowships. Winners will be invited to attend a ceremony at the IBSA Foundation headquarters in Lugano, Switzerland to receive their awards. This year’s IBSA Foundation Fellowship Program awards will be announced in early 2016.

Since 2011, Akrimax and IBSA have worked in collaboration to market Tirosint (levothyroxine sodium capsules) a unique for treatment for hypothyroidism. Tirosint is formulated with just four ingredients: levothyroxine, gelatin, glycerin and water. Clinical studies suggest that Tirosint may be an effective alternative for patients who suffer from tolerability or absorption problems that may be experienced with traditional levothyroxine tablet formulations.

Click here to see Tirosint® Full Prescribing Information including Black Box Warning.

[PR About Hypothyroidism]

[PR About Tirosint]

[PR Tirosint Safety]

[PR About Akrimax]

Click here to see PrimlevTM Full Prescribing Information including Black Box Warning.
Click here to see NitroMist® Full Prescribing Information including Black Box Warning.

[PR Hypothyroidism References]

Contacts

Business Development: J. Gregory Ford, 908-372-1232, gford@akrimax.com
Marketing: Mackenzie Ford, mford@akrimax.com